# Ratio Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ratio-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Boston, US
- Website: www.ratiotx.com/
- Total disclosed funding: $70M
- Latest round: Series C (Jul 16, 2026)
- Investors on record: 5

## About

Based in Massachusetts, US, and founded in 2021 by CEO Jack Hoppin and Director John Babich, Ratio Therapeutics, Inc. operates as a provider of radiotherapeutics treatment and diagnostics by leveraging a technology platform. In July 2026, Ratio Therapeutics, Inc. raised USD 70 million in series C funding from Catalio Capital Management, Eli Lilly and Company, Wasatch Group, Duquesne Family Office LLC Profit Sharing Plan and Bristol-Myers Squibb Company. 

Ratio Therapeutics provides the technology platform trillium, which incorporates a tunable structural motif enabling compounds to reversibly bind to albumin, thereby modulating pharmacokinetics (PK) and improving drug availability and tumour delivery. In addition, the company offers the macropa technology platform, which is used to convert the alpha-emitting radionuclide actinium-225 to trillium and other compounds. The platform provides small molecules, such as peptides, and large polypeptides, such as antibodies. The firm offers clinical stage development for treatment of cancer to diagnose advance programs.

The company will use the July 2026 funding to continue evaluating [Ac-225]RTX-2358 in advanced sarcomas through the ATLAS study and bring its next-generation RLT program closer to clinical testing.

## Funding rounds

- Series C, Jul 16, 2026, $70M — Eli Lilly and Company, Duquesne Family Office, Bristol-Myers Squibb Company, Catalio Capital Management, Wasatch Group

## Investors

- Eli Lilly and Company — Series C
- Duquesne Family Office — Series C
- Bristol-Myers Squibb Company — Series C
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series C
- Wasatch Group — Series C